ACM
BIOS

Atalaya Capital Management’s BioPlus Acquisition Corp. Class A Ordinary Shares BIOS Stock Holding History

Atalaya Capital Management’s Portfolio BIOS Stock Details BIOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-125,000
Closed -$1.3M – 198
2023
Q1 		$1.3M Hold
125,000
– – 0.42% 49
2022
Q4 		$1.28M Sell
125,000
-125,000
-50% -$1.27M 0.23% 82
2022
Q3 		$2.51M Buy
+250,000
New +$2.5M 0.34% 76

Other funds holding BIOS

WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.72B AUM 70.66% 1-Year Est. Return
MSU
Mizuho Securities USA New York $6.2B AUM 35.46% 1-Year Est. Return
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.32B AUM 1.82% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $2.18B AUM 13.58% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
QL
Quarry LP New York $1.2B AUM 47.63% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

Atalaya Capital Management's BIOS Position: Q2 2023 in Review

Atalaya Capital Management sold out of BioPlus Acquisition Corp. Class A Ordinary Shares (BIOS) in Q2 2023, closing a stake of 125,000 shares — an estimated $1.3M sold.

Atalaya Capital Management first reported a position in BIOS in Q3 2022 and held it in 3 quarters. The position peaked at $2.51M in Q3 2022. 32 funds tracked by Wall St. Rank hold BIOS as of Q2 2023.

  • Atalaya Capital Management reported no remaining BioPlus Acquisition Corp. Class A Ordinary Shares position as of Q2 2023 after selling out during the quarter.
  • Atalaya Capital Management sold 125,000 BioPlus Acquisition Corp. Class A Ordinary Shares shares in Q2 2023, an estimated $1.3M.
  • Atalaya Capital Management first reported a position in BioPlus Acquisition Corp. Class A Ordinary Shares in Q3 2022 and held it in 3 quarters.
  • Atalaya Capital Management's BioPlus Acquisition Corp. Class A Ordinary Shares position peaked at $2.51M in Q3 2022.
  • 32 funds tracked by Wall St. Rank held BioPlus Acquisition Corp. Class A Ordinary Shares as of Q2 2023.

Based on Atalaya Capital Management's 13F filing for Q2 2023, filed 9 Aug 2023.